MétaCan
Menu
Back to cohort
Record W2150046646 · doi:10.1016/j.jalz.2012.05.2097

P3‐423: Efficacy of the 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study: Prospective subgroup analysis by disease severity and time‐to‐meet decline

2012· article· en· W2150046646 on OpenAlexaff
Sandra E. Black, Serge Bakchine, Giuseppe Bellelli, José Luís Molinuevo, Pamela Downs, Angelika Caputo, Christine Strohmaier

Bibliographic record

VenueAlzheimer s & Dementia · 2012
Typearticle
Languageen
FieldMedicine
TopicCholinesterase and Neurodegenerative Diseases
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsRivastigmineActivities of daily livingMedicineInternal medicineClinical endpointRandomized controlled trialDiseaseDementiaPhysical therapyDonepezil

Abstract

fetched live from OpenAlex

OPTIMA, a 48-week randomized, double-blind (DB) study, compared the efficacy and safety of 13.3 and 9.5 mg/24 h rivastigmine patches in patients with AD meeting functional and cognitive decline criteria during an initial open-label (IOL) phase with 9.5 mg/24 h patch. The current analysis investigated the efficacy of 13.3 mg/24 h patch on the autonomy in instrumental activities of daily living (IADL) in patients by disease severity and time-to-meet decline criteria. Patients receiving rivastigmine patch 9.5 mg/24 h, were assessed at Weeks 24, 36 and 48 of the IOL phase for functional (investigators' judgement) and cognitive decline (≥2-point decrease in Mini-Mental State Examination [MMSE] score from previous visit OR ≥3-point decrease from baseline). Decliners entered the randomized DB phase (9.5 or 13.3 mg/24 h). Co-primary outcomes included change from DB-baseline at Week 48 on the AD Cooperative Study (ADCS)-IADL scale. Prospective subgroup analyses were efficacy on ADCS-IADL by: disease severity at DB-baseline (moderate [MMSE ≥10 ≤ 18] versus moderate-to-severe [MMSE ≥3 ≤ 18]); and time-to-meet decline criteria (≤ 36 versus >36 weeks). The mean DB-baseline ADCS-IADL score was higher with 13.3 mg/24 h, compared with 9.5 mg/24 h patch, for patients with moderate (26.7 and 24.5, respectively) or moderate-to-severe disease (25.3 and 22.8, respectively). At all time points, regardless of disease severity, slower decline in ADCS-IADL score was observed with 13.3 versus 9.5 mg/24 h patch. The mean DB-baseline ADCS-IADL score was higher with 13.3 mg/24 h, compared with 9.5 mg/24 h patch, for patients meeting decline criteria ≤ 36 weeks (27.1 and 24.5, respectively), but comparable for patients meeting decline criteria >36 weeks. Regardless of time-to-meet decline criteria, decline in ADCS-IADL score was less with 13.3 mg/24 h patch during Weeks 16 to 48.The superiority of the 13.3 mg/24 h patch compared with the 9.5 mg/24 h patch was confirmed by statistical comparisons adjusted for the corresponding baseline value for the different subgroup analyses. High-dose (13.3 mg/24 h) rivastigmine patch demonstrates superior efficacy on functional outcomes and provides additional benefits to patients with AD, compared with 9.5 mg/24 h patch, regardless of their disease severity or time-to-meet decline criteria.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.289
Teacher spread0.264 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicCholinesterase and Neurodegenerative DiseasesFrench-language works237,207